Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

H3K27ac and SMARCB1 binding in control and SMARCB1-knockdown cells

ABSTRACT: H3K27ac and SMARCB1 binding in control and SMARCB1-knockdown cells

PROVIDER: PRJNA506104 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8208600_1.fastq.gz	Fastqsanger.gz
	SRR8208600_2.fastq.gz	Fastqsanger.gz
	SRR8208601_1.fastq.gz	Fastqsanger.gz
	SRR8208601_2.fastq.gz	Fastqsanger.gz
	SRR8208598_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

H3K27ac and SMARCB1 binding in control and SMARCB1-knockdown cells

Project description:This study delineated the downstream activity of oncogenic SMARCB1 and evaluated the genome-wide change of H3K27ac on chromatin.

2021-11-01 | GSE122727 | GEO

Transcriptional response to Smarcb1 re-expression in murine derived Smarcb1 deficient p53 null tumors

Project description:SMARCB1 (Snf5/Ini1/Baf47) is a potent tumor suppressor, the loss of which serves as the diagnostic feature in Malignant Rhabdoid Tumors (MRT) and Atypical Teratoid/Rhabdoid Tumors (AT/RT), two highly aggressive forms of pediatric neoplasms. Here, we restore Smarcb1 expression in cells derived from Smarcb1-deficient tumors which developed in Smarcb1-heterozygous p53-/- mice. Profiling Smarcb1 dependent gene expression we find genes which are dependent on Smarcb1 expression to be enriched for ECM and cell adhesion functions. We identify Igfbp7, which is related to the insulin-like growth factor binding proteins family, as a downstream target of Smarcb1 transcriptional activity, and show that re-introduction of Igfbp7 alone can hinder tumor development. Two cancer cell lines, 167 and 365, derived from Smarcb1-deficient tumors which developed in Smarcb1-heterozygous p53-/- mice were re-infected with a retro-viral vector for Smarcb1 re-expression or an empty retro-viral vector as control. Total-RNA was collected 3 days post infection so as to enrich for direct targets of Smarcb1 transcriptionaly regulated genes

2013-12-31 | E-GEOD-46017 | biostudies-arrayexpress

Smarcb1 is indispensable for the nervous system development and its loss results in a deregulation of esBAF binding [ChIP-seq]

Project description:Using ChIP-seq technology, we aimed to provide insight into the consequences of the knockdown of Smarcb1, an essential esBAF subunit, for the binding of the esBAF complex (Smarca4), the PRC2 complex (Ezh2) as well as for histone marks H3K27me3, H3K27ac and H3K4me3. We show that Smarcb1 knockdown results in the change of BAF complex binding in both directions: decreased binding (potentially by loss of function) as well as increased binding (potentially by retargeting). Furthermore, we see that binding changes especially occur in regions important for basic cellular functions (adhesion, cell organization, metabolism) as well as regions crucial for development (especially nervous system development). In addition, we depicted binding changes in enhancer regions in which a decrease of BAF binding was much more prominent than in gene regions.

2022-04-27 | GSE186667 | GEO

SMARCB1 knockdown in IMR90 and ARPE19

Project description:SMARCB1 knockdown in IMR90 and ARPE19

| PRJNA494666 | ENA

SMARCB1 knockdown in liver cancer cells

Project description:SMARCB1 knockdown in liver cancer cells

| PRJNA419313 | ENA

Knockdown of GRHL2 affects active enhancers (H3K27ac sites) enriched for ER binding

Project description:Knockdown of GRHL2 affects active enhancers (H3K27ac sites) enriched for ER binding

| PRJNA508818 | ENA

A quality control factor for chromatin complexes is synthetic lethal in SMARCB1-mutant cancers

Project description:While oncogenes can potentially be inhibited with small molecules, the loss of tumor suppressors is more common and is problematic because the tumor suppressor proteins are no longer present to be targeted. Notable examples include SMARCB1-mutant cancers, which are highly lethal malignancies driven by the inactivation of a subunit of SWI/SNF chromatin remodeling complexes. To generate mechanistic insight into the consequences of SMARCB1 mutation and to identify vulnerabilities, we contributed 14 SMARCB1-mutant cell lines to a near genome-wide CRISPR screen as part of the Cancer Dependency Map Project1-3. Here, we report that the little-studied gene DDB1-CUL4 Associated Factor 5 (DCAF5) is required for the survival of SMARCB1-mutant cancers. We show that DCAF5 serves a quality control function for SWI/SNF complexes and promotes degradation of incompletely assembled SWI/SNF complexes in the absence of SMARCB1. Upon depletion of DCAF5, SMARCB1-deficient SWI/SNF complexes re-accumulate, bind to target loci, and restore SWI/SNF-mediated gene expression to levels sufficient to reverse the cancer state, including in vivo. Consequently, cancer results not from the loss of SMARCB1 function per se but rather from DCAF5-mediated degradation of SWI/SNF complexes. These data indicate that therapeutic targeting of ubiquitin-mediated quality control factors may effectively reverse the malignant state of some cancers driven by disruption of tumor suppressor complexes.

2024-01-21 | PXD046273 | Pride

A quality control factor for chromatin complexes is synthetic lethal in SMARCB1-mutant cancers

2024-01-21 | PXD046275 | Pride

A quality control factor for chromatin complexes is synthetic lethal in SMARCB1-mutant cancers

2024-01-21 | PXD046276 | Pride

SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability

Project description:We conducted RNA sequencing of control and SMARCB1 knockdown cells at various neural differentiation states

2020-10-01 | GSE157012 | GEO